TKM-080301: Clinical Trials

2 trials of TKM-080301, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 22Completed 2

Follow TKM-080301: new trials by email Literature Review of TKM-080301 trials Research Report on TKM-080301

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
TKM-080301 - Hepatocellular Carcinoma, Hepatoma
Phase 1 / Phase 2CompletedArbutus Biopharma Corporation432014-06-012019-01-16
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
TKM-080301 - Cancer, Neuroendocrine Tumors
Phase 1 / Phase 2CompletedArbutus Biopharma Corporation682010-12-012019-01-16

Conditions studied

Adrenocortical Carcinoma (1)  ·  Carcinoid Tumor (1)  ·  Carcinoma, Hepatocellular (1)  ·  Hodgkin Disease (1)  ·  Liver Neoplasms (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Neoplasms (1)  ·  Neuroendocrine Tumors (1)

Sponsors

Arbutus Biopharma Corporation (2)

Countries

United States (2)  ·  Canada (1)  ·  China (1)  ·  Singapore (1)  ·  South Korea (1)  ·  Taiwan (1)

Top investigators

Mark Kowalski, M.D., Ph.D. (1)  ·  Mark Kowalski, MD (1)

Results publications

PMID 30598500